The advancement of pharmacological treatments
Since the end of the nineteenth century, pharmacology has experienced unprecedented growth, with a offer of medicines that has grown exponentially. However, challenges associated with chronic diseases such as cancer and neurodegenerative conditions continue to represent an urgent need for innovation.
A new clinical trial unit in Osona
Catalonia has traditionally been the nucleus of clinical trials, concentrating mainly in highly complex hospitals. The Osona region is now approaching a significant change with the imminent creation of a unit dedicated to pharmacological research at the University Hospital of Vic.
Financing and infrastructure
The IRIS-CC, an institute dedicated to health science research and innovation, has obtained a grant of 672,000 euros from the Next Generation funds. This investment will be used for the establishment of the new unit, which is already under construction.
A new approach to pharmaceutical research
Dr. Núria Roger, responsible for knowledge transfer, emphasizes that the new installation will be equipped to evaluate emerging treatments and technologies, with the aim of improving the available therapeutic options.
ESPAI I METHODOLOGY
With an area of 200 square meters, the unit will be dedicated to specific clinical trials, separated from care care. It is expected to work with a group of selected patients, guaranteeing a thorough monitoring of their health and data communication with researchers and pharmaceutical companies.
Challenges and Opportunities for the Community
According to José Jerónimo Navas, director of the IRIS-CC, the development of these clinical trials will depend on the interests of health professionals and the needs of the local population. Currently, most clinical trials in Spain focus on oncology and neurology, with a small part dedicated to rare diseases.
Expectations and future of unit
The new clinical trial unit, which is expected to start operating in early September, will not only benefit Osona patients, but will also offer access to innovative treatments that could take years to reach the market. This initiative is a step forward towards a more personalized medicine and adapted to the needs of patients.
Sustainability and collaboration
The initial funding will cover the first two years of operation, after which the unit will have to ensure its sustainability through contracts with the pharmaceutical industry. Comparison with other rehearsal units, such as Althaia, which already carries out numerous annual trials, will be key to its success.
THE VALUE OF THE LOCAL RECERCA
With a reference population of more than 250,000 inhabitants, the goal is for the community to access new therapeutic options without having to move to large hospitals. Roger emphasizes the importance of complying with ethical regulations and principles, ensuring a rigorous and quality approach in each test.
With visits already made by interested laboratories, IRIS-CC continues to establish alliances that will facilitate health innovation for the region, opening a new chapter in pharmaceutical research in Osona.
